Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder

E. H. Cook, Karen Wagner, J. S. March, J. Biederman, P. Landau, R. Wolkow, M. Messig

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Objective: To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD). Method: Children (6-12 years; n=72) and adolescents (13-18 years; n=65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study. Concomitant psychotherapy was allowed during the extension study. Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores. Results: Significant improvement (p<.0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n=132), as well as the child and the adolescent samples. At endpoint, 72% of children and 61% of adolescents met response criteria (>25% decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p<.05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations due to changes in vital signs, laboratory values, or electrocardiograms. Conclusion: Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment.

Original languageEnglish (US)
Pages (from-to)1175-1181
Number of pages7
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume40
Issue number10
StatePublished - 2001
Externally publishedYes

Fingerprint

Sertraline
Obsessive-Compulsive Disorder
Therapeutics
National Institute of Mental Health (U.S.)
Vital Signs
Double-Blind Method
Psychotherapy
Diagnostic and Statistical Manual of Mental Disorders
Electrocardiography
Placebos
Pediatrics
Safety

Keywords

  • Obsessive-compulsive disorder
  • Sertraline

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. / Cook, E. H.; Wagner, Karen; March, J. S.; Biederman, J.; Landau, P.; Wolkow, R.; Messig, M.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 40, No. 10, 2001, p. 1175-1181.

Research output: Contribution to journalArticle

Cook, E. H. ; Wagner, Karen ; March, J. S. ; Biederman, J. ; Landau, P. ; Wolkow, R. ; Messig, M. / Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2001 ; Vol. 40, No. 10. pp. 1175-1181.
@article{0422aa6236254bc4800699ad8a0b1ca7,
title = "Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder",
abstract = "Objective: To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD). Method: Children (6-12 years; n=72) and adolescents (13-18 years; n=65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study. Concomitant psychotherapy was allowed during the extension study. Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores. Results: Significant improvement (p<.0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n=132), as well as the child and the adolescent samples. At endpoint, 72{\%} of children and 61{\%} of adolescents met response criteria (>25{\%} decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p<.05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations due to changes in vital signs, laboratory values, or electrocardiograms. Conclusion: Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment.",
keywords = "Obsessive-compulsive disorder, Sertraline",
author = "Cook, {E. H.} and Karen Wagner and March, {J. S.} and J. Biederman and P. Landau and R. Wolkow and M. Messig",
year = "2001",
language = "English (US)",
volume = "40",
pages = "1175--1181",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder

AU - Cook, E. H.

AU - Wagner, Karen

AU - March, J. S.

AU - Biederman, J.

AU - Landau, P.

AU - Wolkow, R.

AU - Messig, M.

PY - 2001

Y1 - 2001

N2 - Objective: To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD). Method: Children (6-12 years; n=72) and adolescents (13-18 years; n=65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study. Concomitant psychotherapy was allowed during the extension study. Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores. Results: Significant improvement (p<.0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n=132), as well as the child and the adolescent samples. At endpoint, 72% of children and 61% of adolescents met response criteria (>25% decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p<.05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations due to changes in vital signs, laboratory values, or electrocardiograms. Conclusion: Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment.

AB - Objective: To evaluate the safety and effectiveness of sertraline in the long-term treatment of pediatric obsessive-compulsive disorder (OCD). Method: Children (6-12 years; n=72) and adolescents (13-18 years; n=65) with DSM-III-R-defined OCD who had completed a 12-week, double-blind, placebo-controlled sertraline study were given open-label sertraline 50 to 200 mg/day in this 52-week extension study. Concomitant psychotherapy was allowed during the extension study. Outcome was evaluated by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), National Institute of Mental Health Global Obsessive-Compulsive Scale, and Clinical Global Impression Severity (CGI-S) and Improvement (CGI-I) scores. Results: Significant improvement (p<.0001) was demonstrated on all four outcome parameters on an intent-to-treat analysis for the overall study population (n=132), as well as the child and the adolescent samples. At endpoint, 72% of children and 61% of adolescents met response criteria (>25% decrease in CY-BOCS and a CGI-I score of 1 or 2). Significant (p<.05) improvements were also demonstrated from the extension study baseline to endpoint on all outcome parameters in those patients who received sertraline during the 12-week, double-blind acute study. Long-term sertraline treatment was well tolerated, and there were no discontinuations due to changes in vital signs, laboratory values, or electrocardiograms. Conclusion: Sertraline (50-200 mg/day) was effective and generally well tolerated in the treatment of childhood and adolescent OCD for up to 52 weeks. Improvement was seen with continued treatment.

KW - Obsessive-compulsive disorder

KW - Sertraline

UR - http://www.scopus.com/inward/record.url?scp=0034804093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034804093&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 1175

EP - 1181

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 10

ER -